BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 11895798)

  • 1. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.
    Comoli P; Labirio M; Basso S; Baldanti F; Grossi P; Furione M; Viganò M; Fiocchi R; Rossi G; Ginevri F; Gridelli B; Moretta A; Montagna D; Locatelli F; Gerna G; Maccario R
    Blood; 2002 Apr; 99(7):2592-8. PubMed ID: 11895798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs).
    Savoldo B; Goss JA; Hammer MM; Zhang L; Lopez T; Gee AP; Lin YF; Quiros-Tejeira RE; Reinke P; Schubert S; Gottschalk S; Finegold MJ; Brenner MK; Rooney CM; Heslop HE
    Blood; 2006 Nov; 108(9):2942-9. PubMed ID: 16835376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells.
    Comoli P; Maccario R; Locatelli F; Valente U; Basso S; Garaventa A; Tomà P; Botti G; Melioli G; Baldanti F; Nocera A; Perfumo F; Ginevri F
    Am J Transplant; 2005 Jun; 5(6):1415-22. PubMed ID: 15888049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
    Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases.
    Kim N; Sohn HJ; Oh JH; Jeon YW; Lee HJ; Cho HI; Chung BH; Yang CW; Kim TG; Cho SG
    Int J Hematol; 2018 May; 107(5):596-603. PubMed ID: 29188583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
    Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM
    Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
    Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
    Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
    Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
    Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
    Sebelin-Wulf K; Nguyen TD; Oertel S; Papp-Vary M; Trappe RU; Schulzki A; Pezzutto A; Riess H; Subklewe M
    Transpl Immunol; 2007 Apr; 17(3):203-10. PubMed ID: 17331848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review.
    Liu JY; Zhang JM; Zhan HS; Sun LY; Wei L
    Transpl Int; 2021 Dec; 34(12):2483-2493. PubMed ID: 34510581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
    Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T
    J Clin Oncol; 2013 Jan; 31(1):39-48. PubMed ID: 23169501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J; Einsele H; Gil L; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.
    Haque T; Wilkie GM; Taylor C; Amlot PL; Murad P; Iley A; Dombagoda D; Britton KM; Swerdlow AJ; Crawford DH
    Lancet; 2002 Aug; 360(9331):436-42. PubMed ID: 12241714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EBV-specific T-cell immunity in pediatric solid organ graft recipients with posttransplantation lymphoproliferative disease.
    Wilsdorf N; Eiz-Vesper B; Henke-Gendo C; Diestelhorst J; Oschlies I; Hussein K; Pape L; Baumann U; Tönshoff B; Pohl M; Höcker B; Wingen AM; Klapper W; Kreipe H; Schulz TF; Klein C; Maecker-Kolhoff B
    Transplantation; 2013 Jan; 95(1):247-55. PubMed ID: 23222899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
    Riddler SA; Breinig MC; McKnight JL
    Blood; 1994 Aug; 84(3):972-84. PubMed ID: 8043879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients.
    Nalesnik MA; Rao AS; Furukawa H; Pham S; Zeevi A; Fung JJ; Klein G; Gritsch HA; Elder E; Whiteside TL; Starzl TE
    Transplantation; 1997 May; 63(9):1200-5. PubMed ID: 9158009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease.
    Hsieh WS; Lemas MV; Ambinder RF
    Transpl Infect Dis; 1999 Sep; 1(3):204-12. PubMed ID: 11428990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.